Navigation Links
Cowen Group, Inc. Announces 2008 First Quarter Results
Date:5/8/2008

NEW YORK, May 8 /PRNewswire-FirstCall/ -- Cowen Group, Inc. (Nasdaq: COWN) today announced its operating results for the quarter ended March 31, 2008.

Total revenue for the quarter ended March 31, 2008 was $55.0 million, representing a decrease of 25% from $73.5 million in the prior year period. For the quarter ended March 31, 2008, the Company reported net income of $0.7 million, or $0.05 per fully diluted share, compared to net income of $2.5 million in the prior year period, or $0.18 per fully diluted share. The Company's results for the first quarter of 2008 included a reversal of $5.1 million in compensation expense related to amounts previously expensed in 2006 and 2007 associated with the equity award that was forfeited by Kim S. Fennebresque in connection with his resignation as President and Chief Executive Officer. Excluding compensation expense related to employee stock awards in connection with our initial public offering, the Company's adjusted net operating loss for the first quarter of 2008 was $0.6 million compared to its adjusted net operating income of $2.9 million in the prior year period (see "Financial Measures" below for a discussion of adjusted operating income).

"Capital markets conditions, particularly with respect to the new issue market, remained very challenging in the first quarter of 2008," said David M. Malcolm, Chief Executive Officer. "Though our overall results were negatively impacted by lack of new issue market activity, Cowen continued to perform well in other areas including our strategic advisory practice where revenue increased 39% year-over-year and our sales and trading group where core brokerage revenue increased 8% sequentially and was relatively flat year-over-year. I am also pleased with our recent accomplishments in growing the business through continued progress in our alternative asset management area and our proposed geographic expansion into Asia. Our backlog remains strong and I am confident th
'/>"/>

SOURCE Cowen Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
2. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
3. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
4. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. Johnson & Johnson to Participate in the 28th Annual Cowen & Company Health Care Conference
7. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
8. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
9. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
10. Iomai CEO to Speak at Cowen and Company Health Care Conference on Monday, March 17
11. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... new study from Northwestern Medicine has found that surgical researchers ... studies -- despite a huge body of evidence showing that ... , Editors of the five major surgical journals reviewed in ... require authors to state the sex of animals and cells ... in their studies, they will be asked to justify why. ...
(Date:8/28/2014)... (Aug. 28, 2014) Solid-head power toothbrushes ... to researchers at The University of Texas Health ... The results of the study are published in ... Hygiene. Lead author and professor at the UTHealth ... notes that microbial counts were lower in the ...
(Date:8/28/2014)... about datahow to gather it, organize it, and ... analyze and share data lies at the heart ... storage, and analysis of biochemical and biological information ... used in bioinformatics have been instrumental in the ... genomics. But, in the plant sciences, bioinformatics and ...
(Date:8/28/2014)... 28, 2014 Save On Medical ... accelerator program in Tampa. Healthbox Florida has teamed ... companies grow and achieve their goals. , Healthbox ... at their launch event at the Mahaffey Theater to ... Co-founder Matt Schneider commented on the Save On Medical’s ...
(Date:8/28/2014)... Beach, CA (PRWEB) August 28, 2014 ... returns to the more than 100 million people who ... Medicine Report from the Committee on Advancing Pain Research, ... National Institutes of Health, is defined as any pain ... or even longer. And while chronic pain causes range ...
Breaking Medicine News(10 mins):Health News:Females ignored in basic medical research 2Health News:Females ignored in basic medical research 3Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:Together, humans and computers can figure out the plant world 2Health News:Together, humans and computers can figure out the plant world 3Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 2Health News:Interventional Pain Management Expert Glenn M. Lipton, M.D. Shares Common-Sense Tips for Preventing Chronic Pain 3
... News) -- The time between the start of substance abuse ... than for women, a U.S. government report shows. Researchers ... the first time last year and found that the average ... were primarily being treated for was 15.6 years. The ...
... -- Medical researchers are demonstrating that Office of Naval ... mines can help doctors identify and classify cancer-related cells. ... professor at Duke University and developer of the technology. ... The problem that physicians encounter in analyzing images ...
... By Denise Mann HealthDay Reporter , THURSDAY, Oct. ... likely to cause skin cancer than previously believed. New research ... suggests that the main type of ultraviolet rays used in ... of skin that is most vulnerable to the cancer-causing changes caused ...
... Thomas Jefferson University biochemistry researchers have shown for the ... hormone doesn,t activate and repress genes as once thought. In ... a heme-binding receptor to repress the same genes during the ... the last 20 years, the nuclear receptor known as EcR/Usp ...
... Oct. 6 (HealthDay News) -- As many as one-third of Medicare ... of their life, a new Harvard study finds. But ... a tricky one that can only be decided by the doctor, ... medical director at the American College of Surgeons. Nor is ...
... Where you live could play a larger role in ... study by researchers from the Johns Hopkins Bloomberg School ... low-income neighborhood in Baltimore, Maryland and found that, with ... diabetes, obesity among women and use of health services ...
Cached Medicine News:Health News:Mine-hunting software helping doctors to identify rare cells in human cancer 2Health News:Tanning Beds May Be Even Riskier Than Thought 2Health News:Tanning Beds May Be Even Riskier Than Thought 3Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:Many Medicare Patients Get Surgeries in Last Year of Life: Study 2Health News:Place, not race, may be a larger determinant of health disparities 2
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today ... of cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary ... Clostridium difficile ( C. difficile ) infections. ...
Breaking Medicine Technology:Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5
... TRACON Pharmaceuticals, a biotechnology company that develops targeted ... Phase 1 clinical results from studies of TRC105 and ... at the American Society of Clinical Oncology annual meeting ... programs target unique pathways with the potential for broad ...
... Ascenta Therapeutics announced today that eleven presentations or publications ... pan-Bcl-2 inhibitor, in several major tumor types will be ... (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. ... .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
... Four 64 mirrors for complete ... lens rotation. Directly hand held for ... or small holding ring. Small diameter ... gonioscopy without methylcellulose. Advanced technology, multi-layer ...
... Three mirrors of 64, ... small diameter contact surface for ... can be viewed through the ... Multi-layer polymer coating protects mirrors ...
West lacrimal cannula blunt tip with side port....
Medicine Products: